These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15711180)

  • 1. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
    Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
    Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells.
    Temmink OH; Comijn EM; Fukushima M; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1491-4. PubMed ID: 15571283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
    El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.
    de Bruin M; van Capel T; Van der Born K; Kruyt FA; Fukushima M; Hoekman K; Pinedo HM; Peters GJ
    Br J Cancer; 2003 Mar; 88(6):957-64. PubMed ID: 12644837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
    Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
    Temmink OH; Prins HJ; van Gelderop E; Peters GJ
    Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
    Bijnsdorp IV; Peters GJ; Temmink OH; Fukushima M; Kruyt FA
    Int J Cancer; 2010 May; 126(10):2457-68. PubMed ID: 19816940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.
    Temmink OH; Bijnsdorp IV; Prins HJ; Losekoot N; Adema AD; Smid K; Honeywell RJ; Ylstra B; Eijk PP; Fukushima M; Peters GJ
    Mol Cancer Ther; 2010 Apr; 9(4):1047-57. PubMed ID: 20371715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
    Temmink OH; de Bruin M; Turksma AW; Cricca S; Laan AC; Peters GJ
    Int J Biochem Cell Biol; 2007; 39(3):565-75. PubMed ID: 17098463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
    Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
    Murakami Y; Kazuno H; Emura T; Tsujimoto H; Suzuki N; Fukushima M
    Int J Oncol; 2000 Aug; 17(2):277-83. PubMed ID: 10891536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
    Temmink OH; Hoebe EK; Fukushima M; Peters GJ
    Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
    Suetsugu T; Mori R; Futamura M; Fukada M; Tanaka H; Yasufuku I; Sato Y; Iwata Y; Imai T; Imai H; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yoshida K
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
    Azijli K; van Roosmalen IA; Smit J; Pillai S; Fukushima M; de Jong S; Peters GJ; Bijnsdorp IV; Kruyt FA
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
    Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes.
    Suzuki N; Emura T; Fukushima M
    Int J Oncol; 2011 Jul; 39(1):263-70. PubMed ID: 21491084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
    Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
    Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
    Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
    Schwartz EL; Baptiste N; O'Connor CJ; Wadler S; Otter BA
    Cancer Res; 1994 Mar; 54(6):1472-8. PubMed ID: 8137250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.